New report analyzes drug shortages in Canada and their influence on public drug plans

New report analyzes drug shortages in Canada and their influence on public drug plans

The Patented Drugs Costs Evaluation Board (PMPRB) in the present day launched, as a part of the Nationwide Prescription Drug Utilization Data System (NPDUIS) analysis initiative, the Drug Shortages report in Canada and their influence on public drug plans, 2017/18 to 2019/20, which offers an outline of the influence of drug shortages in Canada, with a deal with the results on public drug plans. pharmacare of Canada and their beneficiaries.

OTTAWA, ON, Sept. 21, 2022 /CNW/ – This report is the primary to make use of the Drug Shortages in Canada web site to offer perception into the problem of drug shortages in Canada. The report takes into consideration experiences of drug shortages supplied from April 1, 2017 to March 31, 2020. Its examine interval, which precedes the COVID-19 pandemic, will present future researchers with a benchmark for assessing drug shortages. influence of the pandemic on drug provide.

In accordance with the report, shortages have been reported for 29% of medicine bought in Canada in 2019-20. Nevertheless, 91% of drug scarcity experiences concerned non-patented medicine from a number of sources that might be substituted with a product from one other producer. Subsequently, solely a small variety of shortages have been related to a big drop within the variety of public drug plan beneficiaries submitting claims. These findings present necessary context, however should not meant to reduce the antagonistic results that sure shortages can have on particular person sufferers and on the healthcare system, notably when it’s not doable to substitute different merchandise for the medicine in query. by shortages or when the dosage kind or power of the medicine is just not interchangeable.

Fast Info

• Between April 1, 2017 and March 31, 2020, a complete of 8,558 scarcity experiences have been submitted by Canadian producers, for a median of 238 new experiences monthly.

• In 2019-20, shortages have been reported for 29% of medicine bought in Canada. Generic medicine and medicines with a low remedy price (lower than $10,000/12 months) had larger scarcity charges. No hyperlink has been established between the relative value of medicine internationally and absence charges in Canada.

• The overwhelming majority (91%) of scarcity experiences concerned non-patented medicine from a number of sources, which most often might be substituted with the identical pharmaceutical components from one other producer. Patented medicine and single-source non-patented medicine accounted for 7% and a pair of% of medicine for which a scarcity was reported, respectively.

• Greater than half (55%) of reported drug shortages have been resolved inside three months of their onset. About three-quarters of shortages (74%) have been reported as “resolved” inside six months of their incidence. Shortages of patented medicine and single-source non-patented medicine have been resolved extra rapidly than shortages of non-patented medicine from a number of sources.

• Most shortages don’t considerably disrupt spending tendencies for public plans.

Well being Index publication: 2022-09-22 – Variety of visits since publication: 58

To learn on Well being Index:

#report #analyzes #drug #shortages #Canada #influence #public #drug #plans

Leave a Comment

Your email address will not be published.

Scroll to Top